Vivesto AB Company Description

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden.

Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.

its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma.

The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022.

Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Vivesto AB

Country	Sweden
Founded	1988
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	4
CEO	Erik Kinnman

Contact Details

Address: Gustav III:s Boulevard 46 Solna, 169 73 Sweden
Phone	46 18 50 54 40
Website	vivesto.com

Stock Details

Ticker Symbol	VIVE
Exchange	Nasdaq Stockholm
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0000722365
SIC Code	2836

Key Executives

Name	Position
Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.	Chief Executive Officer
Robert Maiorana	Head of Accounting and Acting Chief Financial Officer
Teresa Fernandez Zafra	Chief Scientific Officer and Head of Preclinical Development & Clinical Operations
Urban Ekelund	IR Manager
John T. Cosby	Head of Regulatory Affairs
Dzianis Babrou	Head of Product Development
Henrik Rönnberg	Chief Medical Officer of Animal Health
Maria Nilsson Hagberg	Head of Regulatory Affairs
Dr. Heidi B. Ramstad	Chief Medical Officer
Johanna Rostin	Chief Regulatory Officer